Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-cash Items: 2019-2025

Historic Non-cash Items for BridgeBio Pharma (BBIO) over the last 6 years, with Jun 2025 value amounting to $10.9 million.

  • BridgeBio Pharma's Non-cash Items fell 83.49% to $10.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.9 million, marking a year-over-year decrease of 83.49%. This contributed to the annual value of $10.3 million for FY2024, which is 94.25% down from last year.
  • As of Q2 2025, BridgeBio Pharma's Non-cash Items stood at $10.9 million, which was down 91.66% from $130.9 million recorded in Q1 2025.
  • Over the past 5 years, BridgeBio Pharma's Non-cash Items peaked at $239.5 million during Q2 2021, and registered a low of $2.0 million during Q1 2021.
  • For the 3-year period, BridgeBio Pharma's Non-cash Items averaged around $61.4 million, with its median value being $57.7 million (2023).
  • Its Non-cash Items has fluctuated over the past 5 years, first slumped by 96.83% in 2021, then soared by 7,851.65% in 2023.
  • BridgeBio Pharma's Non-cash Items (Quarterly) stood at $10.1 million in 2021, then tumbled by 77.87% to $2.2 million in 2022, then skyrocketed by 7,851.65% to $178.6 million in 2023, then slumped by 55.90% to $78.8 million in 2024, then plummeted by 83.49% to $10.9 million in 2025.
  • Its Non-cash Items was $10.9 million in Q2 2025, compared to $130.9 million in Q1 2025 and $78.8 million in Q4 2024.